On September 11, 2025, Arrowhead Pharmaceuticals, Inc. was sued by Ionis Pharmaceuticals for patent infringement related to the '333 patent, following Arrowhead's complaint on September 10, 2025, seeking to declare the patent invalid. This legal dispute is significant for the company.